Boltz Raises $110m Series A to Invest in Compute and Data, Meet Partner Demand and Expand Team

Boltz raised $110m in Series A funding led by Bessemer Venture Partners to invest more deeply in compute and data, meet growing partner demand and expand its team. The AI drug discovery startup also announced partnerships with six of the world’s 20 largest pharmaceutical companies.
- Raised
- $110m
- Round
- Series A
- Investors
- 9
- Investors
- Bessemer Venture PartnersAndreessen HorowitzAmplify PartnersZetta Venture PartnersObvious VenturesGreycroftF-Prime CapitalHummingbirdBenchling
- Target market
- Scientists and pharmaceutical, biotech and industrial companies
- Use of funds
- Investing more deeply in compute and data, meeting growing partner demand and expanding the team
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Boltz?
Boltz raised $110m in Series A funding led by Bessemer Venture Partners to invest more deeply in compute and data, meet growing partner demand and expand its team. The AI drug discovery startup also announced partnerships with six of the world’s 20 largest pharmaceutical companies.
What does Boltz do?
Founded in 2025, Boltz is an AI drug discovery startup based in London, UK. It develops molecular design models and tools for scientists working on medicines, serving pharmaceutical, biotech and industrial companies.
How much did Boltz raise?
Boltz raised $110m in its Series A.
Who invested in Boltz?
Investors named in this Series A include Bessemer Venture Partners, Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, Obvious Ventures, Greycroft, F-Prime Capital and Hummingbird and 1 others.
How will Boltz use the funding?
Boltz plans to use the money for investing more deeply in compute and data, meeting growing partner demand and expanding the team.
Where is Boltz based?
Boltz is based in UK.
Who are the key people at Boltz?
Key people named in this report: Gabriele Corso (Co-Founder and CEO) and Jeremy Wohlwend (Co-Founder).
